Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
复制标题
DOI：
10.3791/50668
复制
发表时间：
2014-06-01
影响因子：
1.2
通讯作者：
Holler, Eggehard
中科院分区：
文献类型：
--
作者：
Ljubimova, Julia Y.;Ding, Hui;Holler, Eggehard
由于分子谱的差异，具有相似等级和形态的肿瘤通常对相同治疗的反应不同。为了解释这种多样性，开发了用于沉默恶性肿瘤相关基因的个性化药物。纳米药物通过靶向肿瘤和递送用于沉默基因的反义寡核苷酸来满足这些需求。由于用于治疗的药物经常重复施用，因此期望没有毒性和可忽略的免疫应答。在这里呈现的实施例中，通过反义寡核苷酸和肿瘤靶向分子的受控化学连接，从生物可降解、无毒和非免疫原性平台聚苹果酸合成纳米药物。使用实验小鼠模型对人Her2阳性乳腺癌的合成和治疗进行了举例说明。这种情况可以转化为其他肿瘤的合成和治疗。
Tumors with similar grade and morphology often respond differently to the same treatment because of variations in molecular profiling. To account for this diversity, personalized medicine is developed for silencing malignancy associated genes. Nano drugs fit these needs by targeting tumor and delivering antisense oligonucleotides for silencing of genes. As drugs for the treatment are often administered repeatedly, absence of toxicity and negligible immune response are desirable. In the example presented here, a nano medicine is synthesized from the biodegradable, non-toxic and non-immunogenic platform polymalic acid by controlled chemical ligation of antisense oligonucleotides and tumor targeting molecules. The synthesis and treatment is exemplified for human Her2-positive breast cancer using an experimental mouse model. The case can be translated towards synthesis and treatment of other tumors.